{"id":"eqw-plus-dapa","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Genital mycotic infections"},{"rate":null,"effect":"Urinary tract infections"},{"rate":null,"effect":"Hypoglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Semaglutide activates GLP-1 receptors to enhance insulin secretion, suppress glucagon, and slow gastric emptying. Dapagliflozin inhibits sodium-glucose cotransporter 2 in the kidney to increase urinary glucose excretion. Together, they provide complementary mechanisms for glycemic control and cardiovascular/renal benefits in type 2 diabetes.","oneSentence":"EQW (semaglutide) is a GLP-1 receptor agonist combined with DAPA (dapagliflozin), an SGLT2 inhibitor, to provide dual glucose-lowering effects through incretin mimicry and urinary glucose excretion.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:11:24.437Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT02635386","phase":"PHASE3","title":"EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)","status":"COMPLETED","sponsor":"Woman's","startDate":"2016-03-22","conditions":"Polycystic Ovary Syndrome, Obesity","enrollment":119}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Bydureon plus Farxiga","Long acting GLP1 agonist plus SGLT2 inhibitor"],"phase":"phase_3","status":"active","brandName":"EQW plus DAPA","genericName":"EQW plus DAPA","companyName":"Woman's","companyId":"woman-s","modality":"Small molecule","firstApprovalDate":"","aiSummary":"EQW (semaglutide) is a GLP-1 receptor agonist combined with DAPA (dapagliflozin), an SGLT2 inhibitor, to provide dual glucose-lowering effects through incretin mimicry and urinary glucose excretion. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}